Arcutis Biotherapeutics, Inc.
ARQT
Rangering i aksjer
#4366
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Aksjekurs
$28.54
Sist synkronisert: 2026-10-16
Markedsverdi
$3.59B
Endring (1 dag)
-1.94%
Endring (1 år)
36.66%
Land
US
Handel Arcutis Biotherapeutics, Inc. (ARQT)
Kategori
Healthcare
EPS for Arcutis Biotherapeutics, Inc. (ARQT)
EPS per June 2026 TTM: $0.22
Ifølge de siste økonomiske rapportene og aksjekursen til Arcutis Biotherapeutics, Inc. er selskapets nåværende EPS (TTM) $0.22. Ved slutten av 2023 hadde selskapet en EPS på $-3.78, en nedgang sammenlignet med EPS-en i 2022 som var $-5.66.
EPS-historikk for Arcutis Biotherapeutics, Inc. fra 2017 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $0.22 | -118.97% |
| 2024 | $-1.16 | -69.31% |
| 2023 | $-3.78 | -33.22% |
| 2022 | $-5.66 | 35.73% |
| 2021 | $-4.17 | 9.74% |
| 2020 | $-3.80 | 245.45% |
| 2019 | $-1.10 | 107.55% |
| 2018 | $-0.53 | -88.75% |
| 2017 | $-4.71 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | 7,772.73% |
US
|
|
| $-7.98 | -3,727.27% |
US
|
|
| $-5.29 | -2,504.55% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 12,509.09% |
NL
|
